Aclaris Therapeutics vs Zenas BioPharma
ACRS and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and ZBIO compare
Zenas BioPharma is the larger company, worth 3.2 times as much as Aclaris Therapeutics ($1.8B against $577M).
Aclaris Therapeutics scores higher on the StockData Score (6 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | ZBIO |
|---|---|---|
| Size and price | ||
| Market cap | $577M | $1.8B |
| Share price | $3.92 | $28.01 |
| Change, 1 year | 62.7% | −21.8% |
| Change, 5 years | −71.6% | – |
| Beta (5Y) | 1.13 | 0.39 |
| Employees | 73 | 167 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 90.1× | – |
| P/B | 3.5× (better) | 8.6× |
| FCF yield | −13.1% (better) | −13.3% |
| Growth | ||
| Revenue growth (TTM) | −59.3% | – |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | −1414% | – |
| Net margin | −1244% | – |
| FCF margin | −1177% | – |
| Return on equity | −55.5% (better) | −265% |
| Financial health | ||
| Debt / equity | 0.00 | 1.05 (better) |
| Current ratio | 5.09 | 9.42 (better) |
| Altman Z-score | −0.44 (better) | −1.46 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 94.0% |
| Held by insiders | 13.3% | 36.1% |
| Insider net buying, 12 months | −$1.4M | $11.4M (better) |
| Short interest, % of float | 9.1% | 27.3% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- ZBIO stock overview
- ZBIO income statement
- ZBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.